European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society Consensus Statement on Diabetic Ketoacidosis in Children and Adolescents

David B. Dunger, MD†‡; Mark A. Sperling, MD†§; Carlo L. Acrerini, MD*; Desmond J. Bohn, MD§; Denis Daneman, MD†§; Thomas P.A. Danne, MD†‡; Nicole S. Glaser, MD§; Ragnar Hanas, MD†‡; Raymond L. Hinz, MD§; Lynne L. Levitsky, MD§; Martin O. Savage, MD†‡; Robert C. Tasker, MD*, and Joseph I. Wolfsdorf, MD§

INTRODUCTION

Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus (TIDM). Mortality is predominantly related to the occurrence of cerebral edema; only a minority of deaths in DKA are attributed to other causes. Cerebral edema occurs in ~0.3% to 1% of all episodes of DKA, and its etiology, pathophysiology, and ideal method of treatment are poorly understood. There is debate as to whether physicians treating DKA can prevent or predict the occurrence of cerebral edema and the appropriate site(s) for children with DKA to be managed. There is agreement that prevention of DKA and reduction of its incidence should be a goal in managing children with diabetes.

To explore these issues, the Lawson Wilkins Pediatric Endocrine Society (LWPES) and the European Society for Pediatric Endocrinology (ESPE) convened a panel of expert physicians for a consensus conference. The meeting was chaired by Mark A. Sperling, MD, representing LWPES, and David B. Dunger, MD, representing ESPE. The Consensus statement was developed with close partnership between the ESPE and LWPES and the International Society for Pediatric and Adolescent Diabetes, all 3 organizations being represented by members who participated in the writing process. The statement was also endorsed by related organizations; the Juvenile Diabetes Research Foundation International, the World Federation of Pediatric Intensive and Critical Care Societies, the European Society for Pediatric Critical Care, the European Society of Pediatric and Neonatal Intensive Care, and the Australian Pediatric Endocrine Group were represented by invited participants.

Each of the major topics had a presenter and recorder, responsible for reviewing the literature and providing evidence-based recommendations according to criteria used by the American Diabetes Association (see Appendix; levels of evidence are indicated in capital letters, in parentheses).1 Type 2 diabetes was not considered. All participants contributed significantly to the development of consensus.

This document summarizes the final consensus reached and represents the current “state of the art.”

DEFINITION OF DKA

DKA is caused by a decrease in effective circulating insulin associated with elevations in counter-regulatory hormones including glucagon, catecholamines, cortisol, and growth hormone. This leads to increased glucose production by the liver
and kidney and impaired peripheral glucose utilization, with resultant hyperglycemia and hyperosmolality. Increased lipolysis, with ketone body (β-hydroxybutyrate [β-OHβ] and acetoacetate) production causes ketonemia and metabolic acidosis. Hyperglycemia and acidosis result in osmotic diuresis, dehydration, and obligate loss of electrolytes. The biochemical criteria for the diagnosis of DKA include hyperglycemia (blood glucose: >11 mmol/L [~200 mg/dL]) with a venous pH <7.3 and/or bicarbonate <15 mmol/L. There is associated glycosuria, ketonuria, and ketonemia. Rarely, young or partially treated children as well as pregnant adolescents may present with near-normal glucose values (“euglycemic ketoacidosis”).2

DKA is generally categorized by the severity of the acidosis, varying from mild (venous pH: <7.30; bicarbonate concentration: <15 mmol/L) to moderate (pH: <7.2; bicarbonate: <10) to severe (pH: <7.1; bicarbonate: <5).3,4

**FREQUENCY OF DKA**

**At Disease Onset**

There is wide geographic variation in the frequency of DKA at diabetes onset, and rates correlate inversely with regional incidence of TIDM. Reported frequencies range between 15% and 67% in Europe and North America and may be more common in developing countries (A).5,6 In Canada and Europe, hospitalization rates for DKA in established and new patients with TIDM have remained stable at ~10 per 100,000 children over the past 20 years, but severity may be decreasing (B).7,8

DKA at onset of TIDM is more common in younger children (<4 years of age), children without a first-degree relative with TIDM, and those from families of lower socioeconomic status (A).4,9 High-dose glucocorticoids, atypical antipsychotics, diazoxide, and some immunosuppressive drugs have been reported to precipitate DKA in individuals not diagnosed previously with TIDM (B).10,11

**In Children With Established TIDM**

The risk of DKA in established TIDM is 1% to 10% per patient per year (A).12–15 Risk is increased in children with poor metabolic control or previous episodes of DKA, peripubertal and adolescent girls, children with psychiatric disorders (including those with eating disorders), and those with difficult family circumstances (including lower socioeconomic status and lack of appropriate health insurance).16 Inappropriate interruption of insulin-pump therapy also leads to DKA.12,14

Children whose insulin is administered by a responsible adult rarely have episodes of DKA (C).17 and 75% of episodes of DKA beyond diagnosis probably are associated with insulin omission or treatment error.17,18 The remainder are due to inadequate insulin therapy during intercurrent illness (B).18–20

**MORBIDITY AND MORTALITY OF DKA IN CHILDREN**

Reported mortality rates from DKA in national population-based studies are reasonably constant: 0.15% (C) (United States), 0.18% (C) (Canada), 0.25% (C) (Canada),2 to 0.31% (B) (United Kingdom).23 In places with less developed medical facilities, the risk of dying from DKA is greater, and children may die before receiving treatment.23

Cerebral edema accounts for between 57% and 87% of all DKA deaths.24,25 The incidence of cerebral edema has been fairly consistent between national population-based studies: 0.46% (C) (Canada), 0.68% (B) (United Kingdom),24 and 0.87% (B) (United States).25 Single-center studies often report higher frequencies because of ascertainment bias arising from secondary referral patterns: 1.1% (C) (United States) to 4.6% (United States).27

Reported mortality rates from cerebral edema in population-based studies are 21% (C), 25% (C), and 24% (B).24 Significant morbidity is evident in 10% (C), 21% (B),25 and 26% (B)24 of survivors. However, some individual centers have reported markedly lower mortality and serious morbidity after DKA and cerebral edema (B [United States26], C [United States27]).

Other possible causes of mortality and morbidity include hypokalemia, hyperkalemia, hypoglycemia, other central nervous system (CNS) complications, hemato ma (C), thrombosis (C), sepsis, infections (including rhinocerebral mucormycosis) (C), aspiration pneumonia, pulmonary edema (C), adult respiratory distress syndrome (C), pneumomediastinum and subcutaneous emphysema (C), and rhabdomyolysis (C). Late sequelae relate to cerebral edema and other CNS complications including hypothalamic-pituitary insufficiency, isolated growth hormone deficiency, and combined growth hormone and thyroid-stimulating hormone deficiency.40

**CEREBRAL EDEMA**

**Presentation**

Cerebral edema typically occurs 4 to 12 hours after treatment is activated but can be present before treatment has begun (B).23 C,42,43 B25 or may develop any time during treatment for DKA. Symptoms and signs of cerebral edema are variable and include onset of headache, gradual decrease or deterioration in level of consciousness, inappropriate slowing of the pulse rate, and an increase in blood pressure (C).44,45

**Pathophysiology**

In vitro experiments and studies in animals and humans presenting with cerebral edema due to other causes (eg, trauma or stroke) suggest that the etiopathological mechanisms may be complex. A number of mechanisms have been proposed, including the role of cerebral ischemia/hypoxia and the generation of various inflammatory mediators, increased cerebral blood flow, and disruption of cell membrane ion transport49,50 and aquaporin channels.51 The generation of intracellular organic osmotolytes (myoinositol and taurine) and subsequent cellular osmotic imbalance has also been implicated.52 Preliminary imaging studies in children with
These associations may be a consequence of the general issues (C).25,27

Risk Factors
Several potential risk factors, at diagnosis or during treatment, have been identified through epidemiologic studies.

- There is evidence that an attenuated rise in measured serum sodium concentrations during therapy for DKA may be associated with increased risk of cerebral edema (C).25,57,58 There is little evidence, however, to show associations between the volume or sodium content of intravenous (IV) fluids or rate of change in serum glucose and risk for cerebral edema (C).25–27,58,59 Therefore, it is unclear whether the association between sodium change and cerebral edema reflects variations in fluid administration or the effects of cerebral injury on renal salt handling.
- There is some evidence to support an association between severity of acidosis and risk of cerebral edema (C).60 There is also evidence for an association between bicarbonate treatment for correction of acidosis and increased risk of cerebral edema (C).25,61
- Greater hypocapnia at presentation of DKA, after adjusting for the degree of acidosis, has been associated with cerebral edema in 2 studies (C).25,27 This association correlates well with the observed detrimental effects of hypocapnia in other conditions (B).62
- Elevated serum urea nitrogen at presentation of DKA is associated with increased risk of cerebral edema (C),25 and this association may reflect greater dehydration in these patients.

Most studies show no association between the degree of hyperglycemia at presentation of DKA with risk of cerebral edema after correcting for other covariates (C).25,27

**MANAGEMENT OF DKA**

**General Issues**
Children with ketosis and hyperglycemia without vomiting or severe dehydration can be managed at home or in an outpatient health care setting (eg, emergency ward or units with similar facilities), but the level of care needs to be reevaluated frequently and supervised by an experienced diabetes team (C,3,63,64 E).

A specialist/consultant pediatrician with training and expertise in the management of DKA should direct inpatient management. The child also should be cared for in a unit that has experienced nursing staff trained in monitoring and management, clear written guidelines, and access to laboratories for frequent evaluation of biochemical variables.

Children with signs of severe DKA (long duration of symptoms, compromised circulation, or depressed level of consciousness) or those who are at increased risk for cerebral edema (including <5 years of age and new onset) should be considered immediately for treatment in an intensive care unit (pediatric, if available) or a child’s ward specializing in diabetes care with equivalent resources and supervision (C,65 E). If transfer by ambulance to another unit is required, caution should be exercised in the use of sedatives and antiemetics.

**Monitoring**
There should be documentation of hour-by-hour clinical observations, IV and oral medication, fluids, and laboratory results during the entire treatment period (E).

Monitoring should include:

- Hourly heart rate, respiratory rate, and blood pressure.
- Hourly (or more frequent), accurate fluid input and output (when there is impaired level of consciousness, urinary catheterization may be necessary).
- In severe DKA, electrocardiogram monitoring may be helpful to assess T-waves for evidence of hyperkalemia/hypokalemia.
- Capillary blood glucose should be monitored hourly (but must be cross-checked against laboratory venous glucose, because capillary methods may be inaccurate in the presence of poor peripheral circulation and acidosis).
- Laboratory tests: electrolytes, urea, hematocrit, blood glucose, and blood gases should be repeated every 2 to 4 hours. (However, electrolytes should be monitored hourly as clinically indicated in the more-severe cases.) An elevated white blood cell count may be due to stress and cannot be taken as a sign of infection.
- Hourly or more-frequent neurologic observations for warning signs and symptoms of cerebral edema:
  - Headache
  - Inappropriate slowing of heart rate
  - Recurrence of vomiting
  - Change in neurologic status (restlessness, irritability, increased drowsiness, or incontinence), or specific neurologic signs (eg, cranial nerve palsies or pupillary response)
  - Rising blood pressure
  - Decreased oxygen saturation

Those monitoring should be instructed to alert the physician of any of these manifestations, because it may be difficult to clinically discriminate cerebral edema from other causes of altered mental status.

**Fluids and Salt (Table 1)**

The high effective osmolality of the extracellular fluid (ECF) compartment results in a shift of water...
from the intracellular fluid (ICF) compartment to the ECF. Studies performed in adults with T1DM in whom insulin therapy was withheld have shown fluid deficits of ~5 L together with ~20% loss of total body sodium and potassium. At the time of presentation, patients are ECF contracted, and clinical estimates of the deficit are usually in the range of 7% to 10%, although these estimates can be subjective and may overestimate the problem. Shock with hemodynamic compromise is a rare event in DKA. The serum sodium measurement is an unreliable measure of the degree of ECF contraction due to the dilutional effect of fluid shift. The effective osmolality (2 [Na + K] + glucose) at the time of presentation is frequently in the range of 300 to 350 mOsm/L. Elevated serum urea nitrogen and hematocrit may be useful markers of severe ECF contraction.

The onset of dehydration is associated with a reduction in glomerular filtration rate (GFR), which results in decreased glucose and ketone clearance from the blood. Studies in humans have shown that IV fluid administration alone results in substantial falls in blood glucose levels because of an increase in GFR. The objectives of fluid and sodium replacement therapy in DKA are 1) restoration of circulating volume, 2) replacement of sodium and the ECF and ICF deficit of water, 3) restoration of GFR with enhanced clearance of glucose and ketones from the blood, and 4) avoidance of cerebral edema.

Both animal and human studies have shown that ICP rises as IV fluids are administered. There are also animal models of DKA that show that the use of hypotonic fluids, compared with isotonic, is associated with greater rises in ICP. Although there are no category A studies that demonstrate superiority of any fluid regimen over another, there are category C data that suggest that rapid fluid replacement with hypotonic fluid is associated with an increased risk of cerebral edema (see “Risk Factors” above). There are both adult (category A) and pediatric (level B) studies that show that a less-rapid fluid-deficit correction with isotonic or near-isotonic solutions results in earlier reversal of acidosis. However, the use of large amounts of 0.9% saline has also been associated with the development of hyperchloremic metabolic acidosis.

There are no data to support the use of colloids in preference to crystalloids in the treatment of DKA. There also are no data to support the use of solutions more dilute than 0.45% NaCl; the use of these solutions, which contain a large amount of electrolyte-free water, is likely to lead to a rapid osmolar change and movement of fluid into the ICF compartment.

**Insulin (Table 2)**

Although rehydration alone causes some decrease in blood glucose concentration, insulin therapy is essential to normalize the blood glucose concentration and suppress lipolysis and ketogenesis. Although different routes (subcutaneous, intramuscular, and IV) and doses have been used, extensive evidence indicates that “low-dose” IV insulin administration should be the standard of care.

Physiologic studies indicate that IV insulin at a dose of 0.1 unit/kg per hour, which achieves steady-state plasma insulin levels of ~100 to 200 μU/mL within 60 minutes, is effective. Such plasma insulin levels are able to offset insulin resistance and, in most circumstances, inhibit lipolysis and ketogenesis, exerting maximal or near-maximal effects on peripheral glucose uptake. The resolution of acidemia invariably takes longer than normalization of blood glucose concentrations.

**Potassium (Table 3)**

Adults with DKA have total body potassium deficits on the order of 3 to 6 mmol/kg; data in children

<table>
<thead>
<tr>
<th>TABLE 1. Water and Salt Replacement in DKA</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Water and salt deficits must be replaced. IV or oral fluids that may have been given before the child presents for treatment and prior to assessment should be factored into calculation of deficit and repair (A).</td>
</tr>
<tr>
<td>• Initial IV fluid administration and, if needed, volume expansion should begin immediately with an isotonic solution (0.9% saline or balanced salt solutions such as Ringer’s lactate). The volume and rate of administration depend on circulatory status, and where it is clinically indicated, the volume is typically 10 to 20 mL/kg over 1 to 2 hours, repeated if necessary (E).</td>
</tr>
<tr>
<td>• Use crystalloid (C).</td>
</tr>
<tr>
<td>• Subsequent fluid management should be with a solution with a tonicity ≥0.45% saline (C):</td>
</tr>
<tr>
<td>• This can be achieved by administering 0.9% saline or balanced salt solution (Ringer’s lactate or 0.45% saline with added potassium) (E).</td>
</tr>
<tr>
<td>• Rate of IV fluid should be calculated to rehydrate evenly over at least 48 hours (E).</td>
</tr>
<tr>
<td>• In addition to clinical assessment of dehydration, calculation of effective osmolality may be valuable to guide fluid and electrolyte therapy (E).</td>
</tr>
<tr>
<td>• Because the severity of dehydration may be difficult to determine and can be overestimated, infuse fluid each day at a rate rarely in excess of 1.5 to 2 times the usual daily requirement based on age, weight, or body surface area. Urinary losses should not be added to the calculation of replacement fluids (E).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 2. Insulin Therapy for DKA</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Correction of insulin deficiency (A):</td>
</tr>
<tr>
<td>• Dose: 0.1 U/kg per hour (A)</td>
</tr>
<tr>
<td>• Route of administration: IV (A)</td>
</tr>
<tr>
<td>• The dose of insulin should remain at least 0.1 U/kg per hour at least until resolution of ketoadacidosis (pH: &gt;30; HCO3: &gt;5 mmol/L and/or closure of anion gap). To prevent an unduly rapid decrease in plasma glucose concentration and possible development of hypoglycemia, glucose should be added to the IV fluid when the plasma glucose falls to ~14 to 17 mmol/L (250–300 mg/dL) (B).</td>
</tr>
<tr>
<td>• There may be circumstances in which the insulin dose may be safely reduced earlier, but the criteria have not been defined (E).</td>
</tr>
<tr>
<td>• If biochemical parameters of ketoadacidosis (pH and anion gap) do not improve, reassess the patient, review insulin therapy, and consider other possible causes of impaired response to insulin (eg, infection, errors in insulin preparation, or adhesion of insulin to tubing with very dilute solutions) (E).</td>
</tr>
<tr>
<td>• There is evidence that an IV bolus of insulin is not necessary (A) (C). However, a bolus may be used at the start of insulin therapy, particularly if insulin treatment has been delayed (E).</td>
</tr>
<tr>
<td>• In unusual circumstances in which IV administration is not possible, the intramuscular or subcutaneous route of insulin administration has been used effectively (C). However, poor perfusion will impair absorption of insulin (E).</td>
</tr>
</tbody>
</table>
are sparse.66,67,82–85 The major loss of potassium is from the intracellular pool as a result of hypotonicity, insulin deficiency, and buffering of hydrogen ions within the cell. Serum potassium levels at the time of presentation may be normal, increased or decreased: Hypokalemia at presentation may be related to prolonged duration of disease, whereas hyperkalemia primarily results from reduced renal function.86 Administration of insulin and the correction of acidosis will drive potassium back into the cells, decreasing serum levels.

**Phosphate**

Depletion of intracellular phosphate occurs and phosphate is lost as a result of osmotic diuresis. In adults, deficits are in the range of 0.5 to 2.5 mmol/kg,66,67,84 but comparable data in children are unavailable. The fall in plasma phosphate levels after starting treatment is exacerbated by insulin administration as phosphate reenters cells.87 Low plasma phosphate levels, when indicative of total body depletion in other conditions, have been associated with a wide array of metabolic disturbances; however, particular interest has focused on erythrocyte 2,3-diphosphoglycerate concentrations and effects on tissue oxygenation.88 Phosphate depletion persists for several days after resolution of DKA.66,82,84 However, prospective studies have failed to show significant clinical benefit from phosphate replacement.89–94 Nevertheless, provided that careful monitoring is performed to avoid hypocalcemia,95,96 potassium phosphate may be used safely in combination with potassium chloride or acetate to avoid hyperchloremia.

**Acidosis**

Even severe acidosis is reversible by fluid and insulin replacement. Administration of insulin stops further ketoacid synthesis and allows excess ketoacids to be metabolized. The metabolism of keto-anion results in the regeneration of bicarbonate (HCO₃⁻) and spontaneous correction of acidemia. Also, treatment of hypovolemia will improve decreased tissue perfusion and renal function, thus increasing the excretion of organic acids (see “Fluids and Salt”) and reversing any lactic acidosis, which may account for 25% of the acidemia.

In DKA, there is an increased anion gap. The major retained anions are β-OHB and acetoacetate.

\[
anion \text{ gap} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) \text{; normally } 12 \pm 2 \text{ mmol/L}
\]

The indications for bicarbonate therapy in DKA are unclear. Several controlled trials of sodium bicarbonate in small numbers of children and adults (B, C) have been unable to demonstrate clinical benefit or any important difference in the rate of rise in the plasma bicarbonate concentration (C).25,97–100

There are potential arguments against the use of bicarbonate.25,97,101,102 Of concern is that bicarbonate therapy may cause paradoxical CNS acidosis and that rapid correction of acidosis caused by bicarbonate will result in hypokalemia and may accentuate sodium load and contribute to serum hypertonicity. In addition, alkali therapy may increase hepatic ketone production, thus slowing the rate of recovery from the ketois.

These findings, however, do not address the issue that there may be select patients who may benefit from cautious alkali therapy, including those with severe acidemia (arterial pH: <6.9) in whom decreased cardiac contractility and peripheral vasodilatation can further impair tissue perfusion and patients with potentially life-threatening hyperkalemia.

**Treatment of Cerebral Edema**

Treatment should be initiated as soon as the condition is suspected. The rate of fluid administration should be reduced. Although mannitol has been shown to have possible beneficial effects in case reports,103–105 there has been no definite beneficial or detrimental effect in retrospective epidemiologic studies.106 The response may be altered by timing of administration, delayed administration being less effective. IV mannitol should be given (0.25–1.0 g/kg over 20 minutes) in patients with signs of cerebral edema before impending respiratory failure (C, E). Repeat in 2 hours if there is no initial response. Hypertonic saline (3%), 5 to 10 mL/kg over 30 minutes, may be an alternative to mannitol (C).107

Intubation and ventilation may be necessary. However, aggressive hyperventilation has been associated with poor outcome in one retrospective study of DKA-related cerebral edema;66 similarly detrimental effects have been reported in numerous other conditions such as head trauma and high-altitude exposure.62 There are no data regarding glucocorticoid use in DKA-related cerebral edema.

---

**TABLE 3.** Potassium, Phosphate, and Acid-Base Management

<table>
<thead>
<tr>
<th>Potassium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Replacement is required (A).</td>
</tr>
<tr>
<td>Replacement therapy should be based on serum potassium measurements (E).</td>
</tr>
<tr>
<td>Start potassium replacement immediately if the patient is hypokalemic; otherwise, start potassium concurrent with starting insulin therapy. If the patient is hyperkalemic, defer potassium until urine output is documented (E).</td>
</tr>
<tr>
<td>Starting potassium concentration in the infusate should be 40 mmol/L (E), and potassium replacement should continue throughout IV fluid therapy (E).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phosphate</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no evidence that replacement has clinical benefit (A).</td>
</tr>
<tr>
<td>Severe hypophosphatemia should be treated (C).</td>
</tr>
<tr>
<td>Potassium phosphate salts may be used as an alternative to or combined with potassium chloride/acetate (C).</td>
</tr>
<tr>
<td>Administration of phosphate may induce hypocalcemia (C).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acid base</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other acute resuscitation protocols no longer recommend bicarbonate administration unless the acidosis is “profound” and “likely to affect the action of adrenaline/epinephrine during resuscitation” (A).</td>
</tr>
<tr>
<td>Fluid and insulin replacement without bicarbonate administration corrects ketoacidosis (A).</td>
</tr>
<tr>
<td>Data show that treatment with bicarbonate confers no clinical benefit (B).</td>
</tr>
<tr>
<td>Repair fluids containing various buffering agents (bicarbonate, acetate, and lactate) have been used (C). The efficacy and safety of these agents have not been established.</td>
</tr>
</tbody>
</table>

http://www.pediatrics.org/cgi/content/full/113/2/e133 e137

Downloaded from by guest on July 17, 2017
PREVENTION OF DKA

Before Diagnosis

Earlier diagnosis through genetic and immunologic screening of high-risk children such as in the recent DPT-1 study decrease DKA incidence at diabetes onset (A). High levels of awareness related to the existence of other members of families with T1DM also reduce the risk of DKA. A school and physician awareness campaign, targeted at 6- to 14-year-olds, reduced rates of DKA from 78% to almost 0% over a 6-year period (B). Increased public awareness of signs and symptoms of diabetes should lead to earlier diagnosis, particularly in children <5 years; checking urine or blood for glucose may prevent misdiagnosis (E). Although such strategies are intuitively obvious, programs to decrease DKA at onset need to be designed and evaluated in diverse populations and age groups.

Beyond Diagnosis

Studies of the effects of comprehensive diabetes programs and telephone help lines report a reduction in the rates of DKA from 15–60 to 5–5.9/100 patient-years (B). In patients on continuous subcutaneous insulin pumps, episodes of DKA can be reduced with the introduction of educational algorithms (E). Therefore, it is likely that episodes of DKA after diagnosis could be reduced if all children with diabetes receive comprehensive diabetes health care and education and have access to a 24-hour diabetes telephone help line (A). The value of home measurement of β-OHB as a mechanism for earlier diagnosis and thus prevention of hospitalization needs to be assessed.

Multiple episodes of recurrent DKA are more problematic: In a recent United Kingdom study, 4.8% of patients accounted for 22.5% of all episodes over a 3-year period. Insulin omission has been identified as the major factor in most of these cases and may be confirmed by finding low free-insulin levels on admission (C). There is no evidence that mental health interventions alone can impact on the frequency of DKA in these children (B). But insulin omission can be prevented by sequential schemes providing education, psychosocial evaluation, and treatment combined with adult supervision of insulin administration (B). When responsible adults administer insulin, a 10-fold reduction in episodes of DKA has been reported (B).

KEY ISSUES FOR FUTURE INVESTIGATION

- Prevention: efficacy and cost-effectiveness of strategies to reduce DKA incidence; frequency and evaluation of ketoacidosis in childhood type 2 diabetes mellitus.
- Management: improved assessment of dehydration; systematic evaluation of rehydration solutions such as those containing bicarbonate, acetate, lactate, and phosphate; use of lower doses of insulin in younger children; clarification of criteria for reducing dose of insulin during treatment of DKA; need for bicarbonate therapy in those with pH <6.9 and the very young.
- Cerebral edema: meta-analysis of existing epidemiologic studies to identify factors related to increased risk in infants and the newly diagnosed; monitoring of DKA and earlier detection of signs of cerebral edema; efficacy of hypertonic saline versus mannitol.

APPENDIX

The American Diabetes Association evidence-grading system for clinical practice recommendations is as follows:

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Clear evidence from well-conducted, generalizable, randomized, controlled trials that are adequately powered, including:</td>
</tr>
<tr>
<td></td>
<td>- Multicenter trial</td>
</tr>
<tr>
<td></td>
<td>- Meta-analysis incorporating quality ratings</td>
</tr>
<tr>
<td></td>
<td>- Compelling nonexperimental evidence, (ie, “all-or-none” rule) developed by the Center for Evidence-Based Medicine at Oxford*</td>
</tr>
<tr>
<td></td>
<td>Supportive evidence from well-conducted, randomized, controlled trials that are adequately powered, including:</td>
</tr>
<tr>
<td>B</td>
<td>- Well-conducted trials at ≥1 institutions</td>
</tr>
<tr>
<td></td>
<td>- Prospective studies or registry</td>
</tr>
<tr>
<td></td>
<td>- Meta-analysis of cohort studies</td>
</tr>
<tr>
<td></td>
<td>Supportive evidence from a well-conducted case-control study.</td>
</tr>
<tr>
<td>C</td>
<td>Supportive evidence from poorly controlled or uncontrolled studies including:</td>
</tr>
<tr>
<td></td>
<td>- Randomized clinical trials with ≥1 major or ≥3 minor methodological flaws that could invalidate the results</td>
</tr>
<tr>
<td></td>
<td>- Observational studies with high potential for bias</td>
</tr>
<tr>
<td></td>
<td>- Case series or case reports</td>
</tr>
<tr>
<td>E</td>
<td>Conflicting evidence with the weight of evidence supporting the recommendation.</td>
</tr>
<tr>
<td></td>
<td>Expert consensus or clinical experience.</td>
</tr>
</tbody>
</table>

* Either all patients died before therapy and at least some survived with therapy or some patients died without therapy and none died with therapy (eg, the use of insulin in the treatment of diabetes ketoacidosis).

ACKNOWLEDGMENTS

The LWIPE and ESPE gratefully acknowledge Aventis Pharmaceuticals, Novo Nordisk, and the Society for Endocrinology for support of the consensus conference; Sten Renstad of Senser for organizing the conference; and Emily Knight and Kathy Wypychowski for assistance with preparing the consensus statement.

REFERENCES


European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society Consensus Statement on Diabetic Ketoacidosis in Children and Adolescents


Pediatrics 2004;113;e133
DOI: 10.1542/peds.113.2.e133

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/113/2/e133.full.html